nach oben

Journal of Neural Transmission

Erschienen in:

01.10.2008 | Parkinson's Disease and Allied Conditions - Review Article

Neuroproteomics as a promising tool in Parkinson’s disease research

verfasst von: Ilse S. Pienaar, William M. U. Daniels, Jürgen Götz

Erschienen in: Journal of Neural Transmission | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Despite the vast number of studies on Parkinson’s disease (PD), its effective diagnosis and treatment remains unsatisfactory. Hence, the relentless search for an optimal cure continues. The emergence of neuroproteomics, with its sophisticated techniques and non-biased ability to quantify proteins, provides a methodology with which to study the changes in neurons that are associated with neurodegeneration. Neuroproteomics is an emerging tool to establish disease-associated protein profiles, while also generating a greater understanding as to how these proteins interact and undergo post-translational modifications. Furthermore, due to the advances made in bioinformatics, insight is created concerning their functional characteristics. In this review, we first summarize the most prominent proteomics techniques and then discuss the major advances in the fast-growing field of neuroproteomics in PD. Ultimately, it is hoped that the application of this technology will lead towards a presymptomatic diagnosis of PD, and the identification of risk factors and new therapeutic targets at which pharmacological intervention can be aimed.

Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9:293–348PubMed

Aebersold R, Rist B, Gygi SP (2000) Quantitative proteome analysis: methods and applications. Ann NY Acad Sci 919:33–47PubMed

Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR (2001) Protein oxidation in the brain in Alzheimer’s disease. Neuroscience 103:373–383PubMed

Alam Z, Daniel S, Lees A, Marsden D, Jenner P, Halliwell P (1997) A generalized increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease. J Neurochem 69:1326–1329PubMed

Andersen JK (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat Med 10:S18–S25PubMed

Arnaudeau S, Frieden M, Nakamura K, Castelbou C, Michalak M, Demaurex N (2002) Calreticulin differentially modulates calcium uptake and release in the endoplasmic reticulum and mitochondria. J Biol Chem 277:46696–46705PubMed

Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC (2001) Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 50:56–63PubMed

Ascherio A, Chen H, Weisskopf MG, O’Reilly E, McCullough ML, Calle EE, Schwarzschild MA, Thun MJ (2006) Pesticide exposure and risk for Parkinson’s disease. Ann Neurol 60:187–203

Bandopadhyay R, Kingsbury AE, Cookson MR, Reid AR, Evans IM, Hope AD, Pittman AM, Lashley T, Canet-Aviles R, Miller DW, McLendon C, Strand C, Leonard AJ, Abou-Sleiman PM, Healy DG, Ariga H, Wood NW, de Silva R, Revesz T, Hardy JA, Lees AJ (2004) The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease. Brain 127:420–430PubMed

Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M (2004) Proteome analysis of human substantia nigra in Parkinson’s disease. Proteomics 4:3943–3952PubMed

Beal MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson’s disease. Ann NY Acad Sci 991:120–131PubMed

Beal MF (2004) Mitochondrial dysfunction and oxidative damage in Alzheimer’s and Parkinson’s diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 36:381–386PubMed

Benecke R, Strümper P, Weiss H (1993) Electron transfer complexes I and IV of platelets are abnormal in Parkinson’s disease but normal in Parkinson-plus syndromes. Brain 116:1451–1463PubMed

Bendiske J, Caba E, Brown QB, Bahr BA (2002) Intracellular deposition, microtubule destabilization, and transport failure: an “early” pathogenic cascade leading to synaptic decline. J Neuropathol Exp Neurol 61:640–650PubMed

Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA (2000) Smoking, alcohol, and coffee consumption preceding Parkinson’s disease. Neurology 55:1350–1358PubMed

Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455PubMed

Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–1306PubMed

Bindoff LA, Birch-Machin M, Cartilidge NE, Parker WD, Turnbull DM (1991) Respiratory chain abnormalities in skeletal muscle from patients with Parkinson’s disease. J Neurol Sci 104:203–208PubMed

Birkmayer W, Hornykiewicz O (1961) The effect of L-3,4-dihydroxyphenylalanine (L-DOPA) on akinesia in Parkinsonism. Wiener Klin. Wochenschr (1998) 73:787–788. Parkinsonism Relat Disord 4:59–60 (English translation)

Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26:231–245PubMed

Bloch F, Houetto JL, Tezenas du Montcel S, Bonneville F, Etchepare F, Welter ML, Rivaud-Pechoux S, Hahn-Barma V, Maisonobe T, Behar C, Lazennec JY, Kurys E, Arnulf I, Bonnet AM, Agid Y (2006) Parkinson’s disease with camptocormia. J Neurol Neurosurg Psychiatry 77:1223–1228PubMed

Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256–259PubMed

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMed

Butterfield DA, Castegna A (2003) Proteomic analysis of oxidatively modified proteins in Alzheimer’s disease brain: insights into neurodegeneration. Amino Acids 25:419–425PubMed

Butterfield DA, Gnjec A, Poon HF, Castegna A, Pierce WM, Klein JB, Martins RN (2006) Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer’s disease: an initial assessment. J Alzheimers Dis 10:391–397PubMed

Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82:1524–1532PubMed

Chen F, David D, Ferrari A, Götz J (2004) Posttranslational modifications of tau: role in human tauopathies and modeling in transgenic animals. Curr Drug Targets 5:503–515PubMed

Chen L, Feany MB (2005) Alpha-synuclein phospohorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson’s disease. Nat Neurosci 8:657–663PubMed

Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A (2005a) Physical activity and the risk of Parkinson disease. Neurology 64:664–669PubMed

Chen Y, Wang Y, Yu H, Wang F, Xu W (2005b) The cross talk between protein kinase A- and RhoA-mediated signaling in cancer cells. Exp Biol Med 230:731–741

Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s diseases. J Biol Chem 279:13256–13264PubMed

Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L (2005) Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 280:11648–11655PubMed

Clark I, Dodson M, Jiang C, Cao J, Huh J, Seol J, Yoo S, Hay B, Guo M (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441:1162–1166PubMed

Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97:571–576PubMed

Conway KA, Rochet JC, Bieganski RM, Lansbury PT (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294:1346–1349PubMed

Cookson MR (2005) The biochemistry of Parkinson’s disease. Annu Rev Biochem 74:29–52PubMed

Corthals GL, Wasinger VC, Hochstrasser DF, Wasinger VC, Hochstrasser DF, Sanchez JC (2000) The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis 21:1104–1115PubMed

Dai J, Buijs RM, Kamphorst W, Swaab DF (2002) Impaired axonal transport of cortical neurons in Alzheimer’s disease is associated with neuropathological changes. Brain Res 948:138–144PubMed

Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909PubMed

David DC, Hauptmann S, Scherping I, Schuessels K, Keil U, Rizzu P, Ravid R, Dröse S, Brandt U, Muller WE, Eckert A, Götz J (2005a) Proteomic and functional analysis reveal a mitochondrial dysfunction in P301L Tau transgenic mice. J Biol Chem 280:23802–23814PubMed

David DC, Hoerndli F, Götz J (2005b) Functional genomics meets neurodegenerative disorders. Part 1: Transcriptomic and proteomic technology. Progress Neurobiol 76:153–168

David DC, Ittner LM, Gehrig P, Nergenau D, Shepherd C, Halliday G, Gotz J (2006) ß-Amyloid treatment of two complementary P301L tau-expressing Alzheimer’s disease models reveals similar deregulated cellular processes. Proteomics 6:6566–6577PubMed

Davidsson P, Sjögren M (2005) The use of proteomics in biomarker discovery in neurodegenerative diseases. Disease Markers 18:1–12

Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson’s disease. Science 302:819–822PubMed

De Hoog CL, Mann M (2004) Proteomics. Annu Rev Genomics Hum Genet 5:267–293PubMed

De Iuliis A, Grigoletto J, Recchia A, Giusti P, Arslan P (2005) A proteomic approach in the study of an animal model of Parkinson’s disease. Clin Chim Acta 357:202–209PubMed

Deumens R, Blokland A, Prickaerts J (2002) Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303–317PubMed

Dexter D, Wells F, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1987) Increased nigral iron content in postmortem parkisonian brain. Lancet 8569:1219–1220

Dexter D, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AH et al (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35:38–44PubMed

Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ (2000) Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 15:459–466PubMed

Escher N, Kaatz M, Melle M, Hipler C, Ziemer M, Driesch D, Wollina U, von Eggeling F (2007) Posttranslational modifications of transthyretin are serum markers in patients with mycosis fungiodes. Neoplasia 9:254–259PubMed

Feany MB, Bender WW (2000) A Drosophila model of Parkinson’s disease. Nature 404:394–398PubMed

Fialka I, Pasquali C, Lottspeich F, Ahorn H, Huber LA (1997) Subcellular fractionation of polarized epithelial cells and identification of organelle-specific proteins by two-dimensional gel electrophoresis. Electrophoresis 18:2582–2590PubMed

Finehout EJ, Franck Z, Lee KH (2005) Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 21:93–101PubMed

Fiskum G, Starkov A, Polster BM, Chinopoulos C (2003) Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson’s disease. Ann NY Acad Sci 99:111–119

Flament-Durand J, Couck AM (1979) Spongiform alterations in brain biopsies of presenile dementia. Acta Neuropathol (Berl) 46:159–162

Fonteh AN, Harrington RJ, Huhmer AF, Biringer RG, Riggings JN, Harrington MG (2006) Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis Markers 22:39–64PubMed

Fornai F, Schluter OM, Lenzi P, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Südhof TC (2005) Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 102:3413–3418PubMed

Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA (1986) Locus coeruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 20:449–455PubMed

Fountoulakis M (2001) Proteomics: current technologies and applications in neurological disorders and toxicology. Amino Acids 21:363–381PubMed

Fountoulakis M (2004) Application of proteomics technologies in the investigation of the brain. Mass Spectrom Rev 23:231–258PubMed

Fountoulakis M, Kossida S (2006) Proteomics-driven progress in neurodegeneration research. Electrophoresis 27:1556–1573PubMed

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164PubMed

Gasser T (2005) Genetics of Parkinson’s disease. Curr Opin Neurol 18:363–369PubMed

Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 294:1346–1349

Giasson BI, Van Deerlin VM (2008) Mutations in LRRK2 as a cause of Parkinson’s disease. Neurosignals 16:99–105PubMed

Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492–501PubMed

Goldknopf IL, Sheta EA, Bryson J, Folsom B, Wilson C, Duty J, Yen AA, Appel SH (2006) Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson’s disease. Biochem Biophys Res Commun 342:1034–1039PubMed

Goldman JE, Yen SH, Chiu FC, Peress NS (1983) Lewy bodies of Parkinson’s disease contain neurofilament antigens. Science 221:1082–1084PubMed

Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ (1998) The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology 50:1346–1350PubMed

Görg A, Postel W, Günther S, Weser J (1985) Improved horizontal two-dimensional electrophoresis with hybrid isoelectric focusing in immobilized pH gradients in the first dimension and laying-on transfer to the second dimension. Electrophoresis 12:653–658

Götz J, Tolnay M, Barmettler R, Ferrari A, Bürki K, Goedert M, Probst A, Nitsch RM (2001) Human tau transgenic mice. Towards an animal model for neuro- and glialfibrillary lesion formation. Adv Exp Med Biol 487:71–83PubMed

Götz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F (2004) Transgenic animal models of Alzheimer’s disease and related disorders: Histopathology, behavior and therapy. Mol Psychiatry 9:664–683PubMed

Götz J, Ittner LM, Kins S (2006) Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer’s disease? J Neurochem 98:993–1006PubMed

Götz J, Deters N, Doldissen A, Bokhari L, Ke Y, Wiesner A, Schonrock N, Ittner LM (2007) A decade of tau transgenic animal models and beyond. Brain Pathol 17:91–103PubMed

Götz J, David D, Hoerndli F, Ke YD, Schonrock N, Wiesner A, Fath T, Bokhari L, Lim YA, Deters N, Ittner LM (2008) Functional genomics dissects pathomechanisms in tauopathies: mitosis failure and unfolded protein response. Neurodegener Dis 5:179–181PubMed

Graves PR, Haystead TA (2002) Molecular biologist’s guide to proteomics. Microbiol Mol Biol Rev 66:39–63PubMed

Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 100:4078–4083PubMed

Gu M, Cooper JM, Taanman JW, Schapira AHV (1998) Mitochondrial DNA transmission of the mitochondrial defect in Parkinson’s disease. Ann Neurol 44:177–186PubMed

Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R (1999) Quantitative analysis of complex protein mixtures using isotope coded affinity tags. Nat Biotechnol 17:994–999PubMed

Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW (1995) Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson’s disease. Ann Neurol 37:714–722PubMed

Hanash S (2004) HUPO initiatives relevant to clinical proteomics. Mol Cell Proteomics 3:298–301PubMed

Hardy J, Cookson MR, Singleton A (2003) Genes and parkinsonism. Lancet Neurol 2:221–228PubMed

Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A (2006) Genetics of Parkinson’s disease and parkinsonism. Ann Neurol 60:389–398PubMed

Hansen L, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A (1990) The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 40:1–8PubMed

He Y, Le WD, Appel SH (2002) Role of fcgamma receptors in nigral cell injury induced by Parkinson’s disease immunoglobulin injection into mouse substantia niga. Exp Neurol 176:322–327PubMed

Heimlick G, Cidlowski JA (2006) Selective role of intracellular chloride in the regulation of the intrinsic but not extrinsic pathway of apoptosis in Jurkat T-cells. J Biol Chem 281:2232–2241

Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284PubMed

Hoving S, Gerrits B, Voshol H, Müller D, Roberts RC, van Oostrum J (2002) Preparative two-dimensional gel electrophoresis at alkaline pH using narrow range immobilized pH gradients. Proteomics 2:127–134PubMed

Hutchens TW, Yip TT (1993) New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 7:576–580

Hoerndli F, David DC, Götz J (2005) Functional Genomics meets neurodegenerative disorders. Part II: application and data integration. Prog Neurobiol 76:169–188PubMed

Hoglinger GU, Carrard G, Michel PO, Medja F, Lombes A, Ruberg M, Friguet B, Hirsch EC (2003) Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson’s disease. J Neurochem 86:1297–1307PubMedCrossRef

Horvatovich P, Govorukhina NI, Reijmers TH, van der Zee AG, Suits F, Bischoff R (2007) Chip-LC-MS for label-free profiling of human serum. Electrophoresis 28:4493–4505PubMed

Hourcade DE, Mitchell L, Kuttner-Kondo LA, Atkinson JP, Medof ME (2002) Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb. J Biol Chem 277:1107–1112PubMed

Huber LA, Pfaller K, Vietor K (2003) Organelle proteomics: implications for subcellular fractionation in proteomics. Circ Res 92:962–968PubMed

Hühmer AF, Biringer RG, Amato H, Fonteh AN, Harrington MG (2006) Protein analysis in human cerebrospinal fluid: physiological aspects, current progress and future challenges. Disease Markers 22:2–26

Ichikawa H, Sugimoto T (2005) Peptide 19 in the rat vagal and glossopharyngeal sensory ganglia. Brain Res 1038:107–112PubMed

Jain KK (2004) Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics 5:331–336PubMed

Jensen PH, Hager H, Nielsen MS, Højrup P, Gliemaann J, Jakes R (1999) α-Synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem 274:25481–25489PubMed

Jin J, Meredith GE, Chen L, Zhou Y, Xu J, Shie FS, Lockhart P, Zhang J (2005) Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson’s disease. Mol Brain Res 134:119–138PubMed

Jin J, Li GJ, Davis J, Zhu D, Wang Y, Pan C, Zhang J (2007) Identification of novel proteins associated with both alpha-synuclein and DJ–1. Mol Cell Proteomics 6:845–859PubMed

Johanson RA, Sarau HM, Foley JJ, Slemmon JR (2000) Calmodulin Binding Peptide PEP–19 Modulates Activation of Calmodulin Kinase II in situ. J Neurosci 20:2860–2866PubMed

Johnson MD, Yu LR, Conrads TP, Kinoshita Y, Uo T, McBee JK, Veenstra TD, Morrison RS (2005) The proteomics of neurodegeneration. Am J Pharmacogenomics 5:259–270PubMed

Jorge I, Casas EM, Villar M, Ortega-Pérez I, López-Ferrer D, Martínez-Ruiz A, Carrera M, Marina A, Martínez P, Serrano H, Cañas B, Were F, Gallardo JM, Lamas S, Redondo JM, García-Dorado D, Vázquez J (2007) High-sensitivity analysis of specific peptides in complex samples by selected MS/MS ion monitoring and linear ion trap mass spectrometry: Application to biological studies. J Mass Spectrom 42:1391–1403PubMed

Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson’s disease. Neuron 37:899–909PubMed

Kinumi T, Kimata J, Taira T, Ariga H, Niki E (2004) Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human. Biochem Biophys Res Commun 317:722–728PubMed

Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Bjorklund A (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22:2780–2791PubMed

Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605–608PubMed

Klein C, Lohmann-Hedrich K (2007) Impact of recent genetic findings in Parkinson’s disease. Curr Opin Neurol 20:453–464PubMed

Klose J (1975) Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 26:231–243PubMed

Klucken J, Shin Y, Hyman BT, McLean PJ (2004) A single amino acid substitution differentiates Hsp70-dependent effects on alpha-synuclein degradation and toxicity. Biochem Biophys Res Commun 325:367–373PubMed

Kurosinski P, Guggisberg M, Götz J (2002) Alzheimer’s and Parkinson’s disease - overlapping or synergistic pathologies? Trends Mol Med 8:3–5PubMed

Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet 18:106–108PubMed

Lee MY, Park SE, Chung KC, Oh YJ (2003) Proteomic analysis reveals upregulation of calreticulin in murine dopaminergic neuronal cells after treatment with 6-hydroxidopamine. Neurosci Lett 352:17–20PubMed

Lee WD, Appel SH (2004) Mutant genes responsible for Parkinson’s disease. Curr Opin Pharmacol 4:79–84

Lee SJ (2008) Origins and effects of extracellular alpha-synuclein: Implications in Parkinson’s disease. J Mol Neurosci 34:17–22PubMed

Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH (1998) The ubiquitin pathway in Parkinson’s disease. Nature 395:451–452PubMed

Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL (1998) Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 339:1105–1111PubMed

Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, Garvik BM, Yates JRIII (1999) Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 17:676–682PubMed

Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O’Connell B, Pollen DA, St George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ (1998) Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153:1365–1370PubMed

Lipton MS, Pasa-Tolic L, Anderson GA (2002) Global analysis of the deinococcus radiodurans proteome by using accurate mass tags. Proc Natl Acad Sci USA 99:11049–11054PubMed

Liu H, Miller E, van de Water B, Stevens JL (2001) Endoplasmic reticulum stress proteins block oxidant-5nd 4ced Ca²⁺ increase and cell death. J Biol Chem 273:12858–12862

Liu H, Zang Y, Wang J, Wang D, Zhou C, Cai Y, Qian X (2006) Method for quantitative proteomics research by using metal element chelated tags coupled with mass spectrometry. Anal Chem 78:6614–6621PubMed

Lopes MF, Melov S (2002) Applied proteomics: Mitochondrial proteins and effect on function. Circ Res 90:380–389

Manetto V, Perry G, Tabaton M, Mulvihill P, Fried VA, Smith HT, Gambetti P, Autilio-Gambetti L (1988) Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases. Proc Natl Acad Sci USA 85:4501–4505PubMed

Manning-Boğ AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 277:1641–1644PubMed

Matsuoka Y, Vila M, Lincoln S, McCormack A, Picciano M, LaFrancois J, Yu X, Dickson D, Langston WJ, McGowan E, Farrer M, Hardy J, Duff K, Przedborski S, Di Monte DA (2001) Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 8:535–539PubMed

Mercken M, Fischer I, Kosik KS, Nixon RA (1995) Three distinct axonal transport rates for tau, tubulin and other microtubule-associated proteins: evidence for dynamic interactions of tau with microtubules in vivo. J Neurosci 15:8259–8267PubMed

Meyer HE, Stuhler K (2007) High-performance proteomics as a tool in biomarker discovery. Proteomics 7:18–26PubMed

Michell AW, Lewis SJG, Foltynie T, Barker RA (2004) Biomarkers and Parkinson’s disease. Brain 127:1693–1705PubMed

Miksys S, Tyndale RF (2006) Nicotine induces brain CYP enzymes: Relevance to Parkinson’s disease. J Neural Transm Suppl 70:177–180PubMedCrossRef

Miller N, Noble E, Jones D, Burn D (2006) Hard to swallow: dysphagia in Parkinson’s disease. Age Ageing 35:614–618PubMed

Mitsumoto A, Nakagawa Y (2001) DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res 35:885–893PubMed

Mitsumoto A, Nakagawa Y, Takeuchi A, Okawa K, Iwamatsu A, Takanezawa Y (2001) Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic Res 35:301–310PubMed

Montgomery EB Jr, Koller WC, LaMantia TJ, Newman MC, Swanson-Hyland AW, Kaszniak AW, Lyons K (2000a) Early detection of probable idiopathic Parkinson’s disease I. Development of a diagnostic test battery. Mov Disord 15:467–473PubMed

Montgomery EB Jr, Lyons K, Koller WC (2000b) Early detection of probable idiopathic Parkinson’s disease II. A prospective application of a diagnostic test battery. Mov Disord 15:474–478PubMed

Moseley MA (2001) Current trends in differential expression proteomics: Isotopically coded tags. Trends Biotechnol 19:S10–S16PubMed

Mueller LN, Rinner O, Schmidt A, Letarte S, Bodenmiller B, Brusniak MY, Vitek O, Aebersold R, Müller M (2007) SuperHirn—a novel tool for high resolution LC-MS-based peptide/protein profiling. Proteomics 7:3470–3480PubMed

Murakami T, Shoji M, Imai Y, Inoue H, Kawarabayashi T, Matsubara E, Harigaya Y, Sasaki A, Takahashi R, Abe K (2004) Pael-R is accumulated in Lewy bodies of Parkinson’s disease. Ann Neurol 55:439–442PubMed

Nakamura K, Bossy-Wetzel E, Burns K, Fadel MP, Lozyk M, Goping IS, Opas M, Bleackley RC, Green DR, Michalak M (2000) Changes in endoplasmic reticulum luminal environment affect cell sensitivity to apoptosis. J Cell Biol 150:731–740PubMed

Neumann M, Muller V, Gorner K, Kretzschmar HA, Haas C, Kahle PJ (2004) Pathological properties of the Parkinson’s disease associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick’s disease. Acta Neuropathol (Berl) 107:489–496

Nissbaum RL, Ellis C (2003) Alzheimer’s disease and Parkinson’s disease. N Engl J Med 348:1356–1364

Nunez MT, Osorio A, Tapia V, Vergara A, Mura CV (2001) Iron-induced oxidative stress up-regulates calreticulin levels in intestinal epithelial (Caco-2) cells. J Cell Biochem 82:660–665PubMed

O’Farrell PH (1975) High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250:4007–4021PubMed

Olanow CW, Tatton WG (1999) Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci 22:123–144PubMed

Olsen JV, Andersen JR, Nielsen PA, Nielsen ML, Figeys D, Mann M, Wisniewski JR (2004) HysTag–a novel proteomic quantification tool applied to differential display analysis of membrane proteins from distinct areas of mouse brain. Mol Cell Proteomics 3:82–92PubMed

Onn SE, Mann M (2005) Mass spectrometry-based proteomics turn quantitative. Nat Chem Biol 1:252–262

Opiteck GJ, Lewis KC, Jorgenson JW, Anderegg RJ (1997) Comprehensive on-line LC/LC/MS of proteins. Anal Chem 69:1518–1524PubMed

Paciello O, Wojcik S, Engel WK, McFerrin J, Askanas V (2006) Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP—overexpressing cultured human muscle fibers. Acta Myol 25:13–22PubMed

Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279:18614–18622PubMed

Pan S, Rush J, Peskind ER, Galasko D, Chung K, Quinn J, Jankovic J, Leverenz JB, Zabetian C, Pan C, Wang Y, Oh JH, Gao J, Zhang J, Montine T, Zhang J (2008) Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res 7:720–730PubMed

Pandey A, Mann M (2000) Proteomics to study genes and genomes. Nature 405:837–846PubMed

Pannese E, Procacci P, Ledda M (1996) Ultrastructural localization of actin in then cell biology of rat spinal ganglion neurons. Anat Embryol 194:527–531PubMed

Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441:1157–1161PubMed

Parker WD, Boyson SJ, Parks JK (1989) Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol 26:719–723PubMed

Parker WD, Parks JK, Swerdlow RH (2008) Complex I deficiency in Parkinson’s disease frontal cortex. Brain Res 1189:215–218PubMed

Pasquali C, Fialka I, Huber LA (1997) Preparative two-dimensional gel electrophoresis of membrane proteins. Electrophoresis 18:2573–2581PubMed

Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EFIII (2001) Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 17:301–307PubMed

Periquet M, Corti O, Jacquier S, Brice A (2005) Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J Neurochem 95:1259–1276PubMed

Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047PubMed

Praprotnik D, Smith MA, Richey PL, Vinters HV, Perry G (1996) Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer’s disease. Acta Neuropathol 91:226–235PubMed

Racette BA, Tabbal SD, Jennings D, Good L, Perlmutter JS, Evanoff B (2005) Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders. Neurology 64:230–235PubMed

Rego AC, Oliveira CR (2003) Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem Res 28:1563–1574PubMed

Reinders J, Lewandrowski U, Moebius J, Wagner Y, Sickmann A (2004) Challenges in mass spectrometry-based proteomics. Proteomics 4:3686–3703PubMed

Richard S, Brion J-P, Couck AM, Flament-Durand J (1989) Accumulation of smooth endoplasmic reticulum in Alzheimer’s disease: new morphological evidence of axoplasmic flow disturbances. J Submicrosc Cytol Pathol 21:461–467PubMed

Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in parkinson’s disease: a detailed study of influential factors in human brain amine analysis. J Neural Transm 38:277–301PubMed

Righetti PG, Campostrini N, Pascali J, Hamdan M, Astner H (2004) Quantitative proteomics: a review of different methodologies. Eur J Mass Spectrom 10:335–348

Romeo M, Espina V, Lowenthal M, Espina BH, Petricoin EF, Liotta LA (2005) CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics 2:57–70PubMed

Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR (2000) Association of coffee and caffeine intake with risk of Parkinson’s disease. JAMA 283:2674–2679PubMed

Schapira AHV, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1:1269PubMed

Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54:823–827PubMed

Schapira AH (1998) Mitochondrial dysfunction in neurodegenerative disorders. Biochem Biophys Acta 1366:225–233PubMed

Schapira AH (2004) Disease modification in Parkinson’s disease. Lancet Neurol 3:362–368PubMed

Schmidt A, Kellermann J, Lottspeich F (2005) A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics 5:4–15PubMed

Schulenborg T, Schmidt O, van Hall A, Meyer HE, Hamacher M, Marcus K (2006) Proteomics in neurodegeneration—disease driven approaches. J Neural Transm 113:1055–1073PubMed

Seniuk NA, Tatton WG, Greenwood CE (1990) Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res 527:7–20PubMed

Setsuie R, Wada K (2007) The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Internat 51:105–111

Shahani N, Brandt R (2002) Functions and malfunctions of the tau-proteins. Cell Mol Life Sci 59:1668–1680PubMed

Shen J, Cookson M (2004) Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron 43:301–304PubMed

Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A (2004) DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2:e362PubMed

Sheta EA, Appel SH, Goldknopf IL (2006) 2-D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Expert Rev Proteomics 3:45–62PubMed

Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC (1991) Mitochondrial oxidative phosporylation defects in Parkinson’s disease. Ann Neurol 30:332–339PubMed

Simpson RJ (2003) Purifying proteins for proteomics: a laboratory manual. Cold Spring Harbor Laboratory Press, New York

Sjögren M, Davidsson P, Tullberg L, Minthon L, Wallin A, Wikkelso C, Granérus AK, Vanderstichele H, Vanmechelen E, Blennow K (2001) Both total and phosphorylated tau are increased in Alzheimer’s disease. J Neurol Neurosurg Psych 70:624–630

Skold K, Svensson M, Nilsson A, Zhang X, Nydahl K, Caprioli RM, Svenningsson P, Andren PE (2006) Decreased striatal levels of PEP-19 following MPTP lesion in the mouse. J Proteome Res 5:262–269PubMed

Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840PubMed

Spiro RG, Zhu Q, Bhoyroo V, Soling HD (1996) Definition of the lectin-like properties of the molecular chaperone, calreticulin, and demonstration of its copurification with endomannosidase from rat liver Golgi. J Biol Chem 271:11588–11594PubMed

Stühler K, Joppich C, Stephan C, Jung K, Müller M, Schmidt O, van Hall A, Hamacher M, Urfen W, Meyer HE, Marcus K (2006) Pilot study of the Human Proteome Organisation Brain Proteome Project: applying different 2-DE techniques to monitor proteomic changes during murine brain development. Proteomics 6:4899–4913PubMed

Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, Butterfield DA (2007) Proteomics analysis of the Alzheimer’s disease hippocampal proteome. J Alzheimers Dis 11:153–164PubMed

Svensson M, Skold K, Nilsson A, Falth M, Svenningsson P, Andren PE (2007) Neuropeptidomics: expanding proteomics downwards. Biochem Soc Trans 35:588–593PubMed

Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP Jr (1996) Origin and functional consequences of the complex I defect in Parkinson’s disease. Ann Neurol 40:663–671PubMed

Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H (2004) EMBO Rep 5:213–218PubMed

The deep-brain stimulation for Parkinson study group (2001) Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Eng J Med 345:956–963

Tinazzi M, Del Vesco C, Fincati E, Ottaviani S, Smania N, Moretto G, Fiaschi A, Martino D, Defazio G (2006) Pain and motor complications in Parkinson’s disease. J Neurol Neurosurg Psych 77:822–825

Tribl F, Marcus K, Bringmann G, Meyer HE, Gerlach M, Riederer P (2006a) Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity. J Neural Transm 113:1041–1054PubMed

Tribl F, Marcus K, Meyer HE, Bringmann G, Gerlach M, Riederer P (2006b) Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle. J Neural Transm 113:741–749PubMed

Trojanowski JQ, Lee VM (1998) Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 55:151–152PubMed

Truong DD, Bhidayasiri R, Wolters E (2007) Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci 266:216–228PubMed

Tseng H-M, Su PC, Liu H-M, Liou H-H, Yen R-F (2007) Bilateral subthalamotomy for advanced Parkinson disease. Surg Neurol 68:S43–S50PubMed

Utal AK, Stopka AL, Roy M, Coleman PD (1998) PEP-19 immunohistochemistry defines the basal ganglia and associated structures in the adult human brain and is dramatically reduced in Huntington’s disease. Neuroscience 86:1055–1063PubMed

Utton MA, Connell J, Asuni AA, Van Slegtenhorst M, Hutton M, De Silva R, Lees AJ, Miller CC, Anderton BH (2002) The slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants in cultured neurons. J Neurosci 22:6394–6400PubMed

Vercauteren FGG, Bergeron JJM, Vandesande F, Arckens L, Quirion R (2004) Proteomic approaches in brain research and neuropharmacology. Eur J Pharmacol 500:385–398PubMed

Vila-Carriles WH, Zhou ZH, Bubien JK, Fuller CM, Benos DJ (2007) Participation of the chaperone Hsc70 in the trafficking and functional expression of ASIC2 in glioma cells. J Biol Chem 282:34381–34391PubMed

von Bohlen und Halbach O, Schober A, Krieglstein K (2004) Genes, proteins, and neurotoxins involved in Parkinson’s disease. Prog Neurobiol 73:151–177

Waragai M, Nakai M, Wei J, Fujita M, Mizuno H, Ho G, Masliah E, Akatsu H, Yokochi F, Hashimoto M (2007) Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson’s disease. Neurosci Lett 425:18–22PubMed

Washburn MP, Yates JR (2000) Analysis of the microbial proteome. Curr Opin Microbiol 3:292–297PubMed

Washburn MP, Ulaszek R, Deciu C, Schieltz DM, Yates JR (2002) Analysis of quantitative proteomic data generated via multidimensional protein identification technology. Anal Chem 74:1650–1657PubMed

Wiederkehr F (1991) Analysis of cerebrospinal fluid proteins by electrophoresis. J Chromatogr 569:281–296PubMed

Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery-Smith I, Ochstrasser DF, Williams KL (1996) Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 13:19–50PubMed

Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J (1989) The neuron-specific protein PGP9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246:670–673PubMed

Wolters EC, Francot C, Bergmans P, Winogrodzka A, Booij J, Berendse HW, Stoof HC (2000) Preclinical (premotor) Parkinson’s disease. J Neurol 247:II103–II109PubMed

Wolters DA, Washburn MP, Yates JR (2001) An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 73:5683–5690PubMed

Wood-Allum CA, Barber SC, Kirby J, Heath P, Holden H, Mead R, Higginbottom A, Allen S, Beaujeux T, Alexson SE, Ince PG, Shaw PJ (2006) Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen. Brain 128:1686–1706

Wu CC, MacCoss MJ (2002) Shotgun proteomics: tools for the analysis of complex biological systems. Curr Opin Mol Ther 4:242–250PubMed

Wu TL (2006) Two-dimensional difference gel electrophoresis. Methods Mol Biol 328:71–95PubMed

Xun Z, Sowell RA, Kaufman TC, Clemmer DE (2007) Lifetime proteomic profiling of an A30P α-synuclein drosophila model of Parkinson’s disease. J Proteome Res 6:3729–3738PubMed

Yao H, Sem DS (2005) Cofactor fingerprinting with STD NMR to characterize proteins of unknown function: identification of a rare cCMP cofactor preference. FEBS Lett 579:661–666PubMed

Yokota T, Sugawara K, Ito K, Takahashi R, Ariga H, Mizusawa H (2003) Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun 312:1342–1348PubMed

Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman E, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson’s disease. Proc Natl Acad Sci USA 93:2696–2701PubMed

Zang L, Toy DP, Hancock WS, Sgroi DC, Karger BL (2004) J Prot Res 3:604–612

Zetterberg H, Ruetschi U, Portelius E, Brinkmalm G, Andreasson U, Blennow K, Brinkmalm A (2008) Clinical proteomics in neurodegenerative disorders. Acta Neurol Scand (in press)

Zigmond MJ, Burke RE (2002) Pathophysiology of Parkinson’s disease. In: Davis KL, Coyle J, Charney D, Nemeroff C (eds) Fifth Generation of Progress. Lippincott Williams & Wilkins, Philadelphia, pp 1781–1794

Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, Martinez D, Joyce S, Trojanowski JQ, Lee VM (2004) Retarded axonal transport of R406 W mutant tau in transgenic mice with a neurodegenerative tauopathy. J Neurosci 24:4657–4667PubMed

Zhou Y, Gu G, Goodlett DR, Zhang T, Pan C, Montine TJ, Montine KS, Aebersold RH, Zhang J (2004) Analysis of α-synuclein associated proteins by quantitative proteomics. J Biol Chem 279:39155–39164PubMed

Zhou W, Freed CR (2005) DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T α-synuclein toxicity. J Biol Chem 280:43150–43158PubMed

Zhou W, Zhu M, Wilson MA, Petsko GA, Fink LA (2006) The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J Mol Biol 356:1036–1048PubMed

Zhu M, Qin ZJ, Hu D, Munishkina LA, Fink AL (2006) Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. Biochemistry 45:8135–8142PubMed

Titel: Neuroproteomics as a promising tool in Parkinson’s disease research
verfasst von: Ilse S. Pienaar
William M. U. Daniels
Jürgen Götz
Publikationsdatum: 01.10.2008
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 10/2008
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-008-0070-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2008

Externally provoked freezing of gait in open runways in advanced Parkinson’s disease results from motor and mental collapse

Automatic striatal volumetry allows for identification of patients with chorea-acanthocytosis at single subject level

Genetic association analysis of tagging SNPs in alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRNB2) with schizophrenia in the Japanese population

High number of striatal dopaminergic neurons during early postnatal development: correlation analysis with dopaminergic fibers

Slow cortical potential neurofeedback in attention deficit hyperactivity disorder: is there neurophysiological evidence for specific effects?